Skip to main content

HomeResearchCompareAOD-9604 vs IGF-DES

Peptide Comparison

AOD-9604 vs IGF-DES

Both are GH / IGF Axis peptides.

AOD-9604

Advanced Obesity Drug 9604

Fat LossResearch Only

Half-life: 30–60 minutes

197 providers listed

Full AOD-9604 profile →
vs

IGF-DES

des(1-3)IGF-1

PerformanceResearch Only

3 providers listed

Full IGF-DES profile →
Bottom line

AOD-9604 has published research citations on file; IGF-DES does not yet — the main evidence gap between them.

Quick Verdict

AOD-9604

Half-life

30–60 minutes

IGF-DES

Half-life

Which One Should You Choose?
Your goalBetter option
Has published research citationsAOD-9604
Oral administration optionAOD-9604
More provider options (197 vs 3)AOD-9604

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison
AOD-9604
IGF-DES
Mechanism Family
GH / IGF Axis
GH / IGF Axis
Half-life
30–60 minutes
FDA Status
nomination withdrawn
unknown
Admin Routes
subcutaneous, oral
subcutaneous, intramuscular
Availability
Research Only
Research Only
Providers
197 listed
3 listed
Avail. Notes
HGH fragment 176-191. Drug development terminated 2007 (Phase 3 failure). FDA GRAS notice GRN 000792 for food ingredient use only — not a drug approval. No active NDA. Research chemical.
Research Evidence

AOD-9604

Animal · 1 key study · dated evidence base — most recent 2001

IGF-DES

No citations on file
Research Citations

About AOD-9604

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

Research Areas
selective fat tissue lipolysis via GH C-terminal fragment mechanismadipose metabolism stimulation without IGF-1 elevationoriginally developed to isolate GH lipolytic effect from growth effectssubcutaneous injection — reconstitution with bacteriostatic water required

About IGF-DES

N-terminal truncation eliminates IGFBP binding, leaving nearly all circulating IGF-DES unbound and active. Results in substantially higher tissue IGF-1R activation versus native IGF-1 at equivalent doses. Activates PI3K/Akt/mTOR for muscle hypertrophy and satellite cell proliferation.

Research Areas
muscle hypertrophylocalized anabolismsatellite cell activationtissue growth
Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

AOD-9604

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

IGF-DES

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Price (per mg)

AOD-9604

$9.00/mg

$7.71$11.85 range

45 vendors

IGF-DES

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More GH / IGF Axis Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). AOD-9604 vs IGF-DES — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/aod-9604/igf-des

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.